Treatment of recurrent cyclical mastodynia in patients with fibrocystic breast disease

Anton Döberl, Tobias Tobiassen, Thorkild Rasmussen
In: Acta Obstetricia et Gynecologica Scandinavica · 1984 · vol. 63(S123) , pp. 177–184 · doi:10.3109/00016348409157007 · PMID:6388218 · W2125247590
article OA: closed CC0 ⤵ 7 in-corpus citations
View on OpenAlex View on PubMed View at publisher
⚙ AI-generated summary by claude@2026-06, 2026-06-07 ⓘ

Danazol treatment significantly reduced cyclical mastodynia and improved breast findings in premenopausal women with fibrocystic disease compared to placebo.

One-sentence paraphrase of the abstract; not a substitute for reading it. No clinical advice. How this works

Abstract

Thirty premenopausal women with recurrent, pronounced cyclical mastodynia associated with mammographically confirmed fibrocystic disease were studied. All patients had long-standing symptoms, had undergone one previous course of treatment with danazol, and were recruited during long-term follow-up after original treatment, when cyclical mastodynia had again reached similar severity as before the original treatment (mean interval between treatments 9.5 +/- 3.9 (SD) months). Fifteen patients each were randomly allocated to double-blind treatment with either danazol or placebo. During the first month, 2 capsules a day (each containing danazol 100 mg or placebo) were given, thereafter one capsule a day up to 6 months. Danazol caused a marked and sustained decrease in mastodynia, according to the clinician's assessment and according to each patient's self-rating on a visual analogue scale. The response to danazol was fairly uniform and statistically significant (p less than 0.005 or less), whereas the response to placebo was inconsistent and not statistically significant (p greater than 0.10). Danazol proved significantly more effective than placebo (p less than 0.05 or less). Changes in palpatory and/or mammographic findings were also found more consistently after danazol treatment than after placebo. During treatment, there was a modest weight increase, which was statistically significant in the danazol group (p less than 0.01) but not in the placebo group. A greater frequency in menstrual irregularities was observed in the danazol group than in the placebo group, but not to an extent that would have caused 'unblinding' of the study.(ABSTRACT TRUNCATED AT 250 WORDS)

My notes (saved in your browser only)

Citation neighborhood

Papers in the corpus that this work cites (lower rings, blue) and that cite this one (upper rings, green). Dot size scales with the paper's in-corpus citation count — bigger dot = more influential within the endo/adeno field. Click a dot to open that paper. [ expand to 2 hops ] — adds papers reached through this work's immediate citers/citees. Heavier; up to 60 extra dots.

References (11)

Cited by (7)

SciLite annotations

chemicals 7
danazol danazol danazol danazol danazol danazol danazol

Source provenance

openalex
last seen: 2026-05-10T11:10:35.749868+00:00
scilite
last seen: 2026-05-18T04:25:29.313245+00:00
unpaywall
last seen: 2026-06-02T02:00:03.124865+00:00
License: CC0 · commercial use OK